Core Viewpoint - The news highlights the positive performance of the major consumption index and related ETFs, driven by recent monetary policy measures and expectations for consumer spending growth in China [3][4]. Group 1: Market Performance - As of May 8, 2025, the major consumption index (000932) increased by 0.11%, with notable gains from stocks such as New Nuo Wei (300765) up 2.27% and Wuliangye (000858) up 1.28% [3]. - The major consumption ETF (159672) also rose by 0.13%, marking its fourth consecutive increase, with a trading volume of 318.23 million yuan and a turnover rate of 3.79% [3]. - The average daily trading volume for the major consumption ETF over the past month was 595.10 million yuan as of May 7, 2025 [3]. Group 2: Policy and Economic Outlook - The Central Committee's recent meeting emphasized increasing income for low- and middle-income groups and boosting service consumption to enhance economic growth [4]. - The meeting's continuation of previous policy stances strengthens expectations for consumer policy, leading to an optimistic outlook for the consumption sector [4]. Group 3: Investment Strategies - The report suggests that the liquor sector is at a fundamental bottom, recommending increased allocation to quality liquor companies with potential market share growth [4]. - Three main investment strategies are proposed: focusing on channel reforms and new product categories, anticipating a slight recovery in the restaurant sector, and identifying companies benefiting from cost reductions [4]. Group 4: ETF Performance Metrics - The major consumption ETF has achieved a maximum monthly return of 24.35% since its inception, with an average monthly return of 5.36% during rising months [5]. - As of May 7, 2025, the ETF's year-to-date maximum drawdown was 5.57%, with a relative benchmark drawdown of 0.34% [5]. - The ETF's management fee is 0.50% and the custody fee is 0.10%, making it one of the lowest in its category [5]. Group 5: Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the major consumption index is 19.9, indicating it is at a historical low, being below 94.05% of the time over the past year [5]. - As of April 30, 2025, the top ten weighted stocks in the index accounted for 67.16% of the total, with notable companies including Yili (600887) and Kweichow Moutai (600519) [5][7].

Core Viewpoint - New Nuo Wei (300765.SZ) has terminated its acquisition of Shiyao Baike, with the Shenzhen Stock Exchange halting the review of the asset purchase and fundraising application due to changes in the pharmaceutical industry and capital market conditions since the initial planning of the restructuring [1][3]. Group 1: Acquisition Details - The acquisition was initially approved by New Nuo Wei's board in January 2024, intending to purchase 100% of Shiyao Baike for a total consideration of 7.6 billion yuan, with 90% paid in shares and 10% in cash [2][3]. - The transaction was expected to enhance New Nuo Wei's biopharmaceutical portfolio, particularly in long-acting proteins and innovative drug pipelines [2][3]. Group 2: Financial Performance - New Nuo Wei has experienced a decline in revenue and net profit for two consecutive years, with revenues of 25.39 billion yuan in 2023 and 19.81 billion yuan in 2024, representing year-on-year decreases of 4.75% and 21.98%, respectively [6]. - The net profit for 2023 and 2024 was reported at 4.34 billion yuan and 537.26 million yuan, showing declines of 40.18% and 87.63% year-on-year [6]. - In Q1 2025, New Nuo Wei reported revenues of 472 million yuan, a 9.94% decrease year-on-year, and a net loss of 26.90 million yuan compared to a profit of 79.06 million yuan in the same period the previous year [8]. Group 3: R&D and Market Conditions - The company has significantly increased its R&D expenditures, reaching 840 million yuan in 2024, a 25.44% increase from the previous year, with Q1 2025 R&D expenses at 240 million yuan, up 117.68% year-on-year [6][9]. - New Nuo Wei's strategic focus includes ADCs, mRNA vaccines, and antibody drugs, with over 20 products in the pipeline and several achieving important milestones in 2024 [7].

Group 1 - The core point of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed Fund C, which has shown significant returns over various time frames despite a recent decline in net value [1] - As of May 7, 2025, the latest net value of the fund is 1.6149 yuan, reflecting a decrease of 3.58%. The fund has achieved a return of 17.34% over the past month, ranking 231 out of 4587 in its category [1] - The fund's performance over the last three months has been strong, with a return of 34.96%, ranking 16 out of 4535, and a year-to-date return of 36.23%, ranking 31 out of 4494 [1] Group 2 - The top ten stock holdings of the Zhongyin Innovation Medical Mixed Fund C account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] - The fund was established on October 30, 2020, and as of March 31, 2025, it has a total scale of 1.454 billion yuan, managed by fund manager Zheng Ning [1]

Core Insights - The latest net value of ICBC Frontier Medical Stock A (001717) is 2.8300 yuan, reflecting a decrease of 1.77% [1] - The fund has shown a one-month return of 5.28%, ranking 400 out of 471 in its category; a three-month return of 8.06%, ranking 71 out of 471; and a year-to-date return of 7.56%, ranking 113 out of 469 [1] Fund Holdings - The top ten holdings of ICBC Frontier Medical Stock A account for a total of 59.05%, with the largest positions being: - Heng Rui Medicine (10.11%) - Kelun Pharmaceutical (8.01%) - WuXi AppTec (7.72%) - BeiGene (6.85%) - Xinlitai (4.90%) - Zai Lab (4.77%) - Yuyue Medical (4.60%) - New Horizon Health (4.36%) - East China Pharmaceutical (4.20%) - Haizhi Pharmaceutical (3.53%) [1] Fund Overview - ICBC Frontier Medical Stock A was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector [2]

简历显示：吴兴武先生:中国籍,理学硕士,持有中国证券投资基金业从业证书,曾任摩根士丹利华鑫基金 管理有限公司研究员,广发基金管理有限公司研究发展部、权益投资一部研究员、广发多元新兴股票型 证券投资基金基金经理(自2017年4月25日至2019年4月16日)、广发核心精选混合型证券投资基金基金经 理(自2015年2月17日至2020年2月10日)、广发鑫瑞混合型证券投资基金(LOF)基金经理(自2019年4月16 日至2020年7月29日)、广发再融资主题灵活配置混合型证券投资基金(LOF)基金经理(自2019年4月16日 至2020年7月31日)。现任广发轮动配置混合型证券投资基金基金经理(自2015年2月12日起任职)、广发医 疗保健股票型证券投资基金基金经理(自2018年10月16日起任职)、广发医药健康混合型证券投资基金基 金经理(自2020年10月21日起任职)、广发创新医疗两年持有期混合型证券投资基金基金经理(自2021年3 月19日起任职)。2022年11月4日起任广发竞争优势灵活配置混合型证券投资基金基金经理。曾任广发主 题领先灵活配置混合型证券投资基金基金经理。 来源：金融界 公开资料显示，广 ...

金融界2025年5月7日消息，汇添富医疗服务灵活配置混合A(001417) 最新净值1.5080元，下跌2.27%。该 基金近1个月收益率10.88%，同类排名84|2324；近3个月收益率27.91%，同类排名5|2317；今年来收益 率25.25%，同类排名17|2306。 简历显示：张韡女士:中国。康奈尔大学生物医学硕士,曾任东方证券医药助理研究员,汇添富基金医药研 究员、高级医药研究员及医药行业研究组组长。2021年9月29日起任汇添富香港优势精选混合型证券投 资基金基金经理。2022年10月21日担任汇添富达欣灵活配置混合型证券投资基金基金经理。2023年11月 23日起担任汇添富医疗服务灵活配置混合型证券投资基金基金经理。2023年11月23日任汇添富全球医疗 保健混合型证券投资基金基金经理。现任汇添富创新医药主题混合型证券投资基金基金经理。 来源：金融界 汇添富医疗服务灵活配置混合A股票持仓前十占比合计64.17%，分别为：恒瑞医药（10.23%）、科伦药 业（9.09%）、百利天恒（8.94%）、海思科（8.27%）、信立泰（6.66%）、泽璟制药-U（6.10%）、新 诺威（4.69%）、荣 ...

Group 1: Termination of Asset Restructuring - The termination of the asset restructuring will not have a significant adverse impact on the company's existing operations and strategic planning [1][2][4] - The decision to terminate the restructuring was made after careful consideration of the pharmaceutical industry and capital market conditions [2][4] - The company will not plan any major asset restructuring for at least one month following the announcement of the termination [2][4] Group 2: Business Operations and Future Plans - The company will continue to focus on research and development, enhancing drug development efficiency [2][3][4] - Ongoing projects, including the construction of production lines for monoclonal antibodies and ADC new products, are progressing normally [3][4] - As of April 30, 2025, the number of shareholders was 12,217 [2][5] Group 3: Innovation and Market Strategy - The company aims to establish a comprehensive research pipeline by continuously exploring new molecules and maintaining a high-efficiency research progress [2][3] - Future product lines will focus on cutting-edge areas such as ADC, mRNA vaccines, and antibody drugs [2][5] - The company is committed to creating greater value for investors through sustained innovation and improved management [2][4]

Group 1 - In April, among 1016 comparable ordinary stock funds, 171 funds saw an increase in performance, 3 remained flat, and 842 experienced a decline [1][2] - The pharmaceutical and biopharmaceutical sectors emerged as the leading sectors, significantly boosting the performance of related thematic funds [1][2] - Notable funds with over 10% growth in April include Bank of China Health Stock A (12.65%), Bank of China Health Stock C (12.61%), and Penghua Pharmaceutical Technology Stock A (11.65%) [1][2] Group 2 - Bank of China Health Stock A and C's top ten holdings include major companies such as Heng Rui Medicine, Xin Nuo Wei, and Bai Li Tian Heng [1] - Penghua Pharmaceutical Technology Stock A and C, managed by veteran Jin Xiaofei, reported increases of 11.65% and 11.62% respectively, with significant holdings in companies like Nuo Cheng Jian Hua and Bai Ji Shen Zhou [2] - Hua An Pharmaceutical Biotechnology Stock A and C also performed well, with monthly growth rates of 10.91% and 10.88% [2] Group 3 - On the downside, nine ordinary stock funds fell over 10% in April, primarily in the consumer electronics and new energy sectors [3][4] - Minsheng Jia Yin Preferred Stock Fund recorded the largest decline at -13.71%, with major holdings including Haier Smart Home and BYD [3] - Other funds like Dongwu Double Triangle Stock A and C also faced significant declines of 11.09% and 11.14% respectively, largely due to their investments in new energy and internet platforms [4] Group 4 - HSBC Jin Trust Low Carbon Pioneer Stock A and C experienced declines of 10.07% and 10.11%, with all top holdings in new energy stocks [4] - The cumulative return of HSBC Jin Trust Low Carbon Pioneer Stock C since its inception is a loss of 58.24% as of April 30 [4] - The management of these funds includes experienced professionals with extensive backgrounds in research and investment [3][4]

Group 1 - In April 2025, out of 8,451 comparable mixed funds, 1,899 funds saw an increase in net value, while 6,529 funds experienced a decline, and 23 funds remained flat [1] - The top two performing funds for April were Zhonghang Youxuan Lihang Mixed Fund A and C, with returns of 17.30% and 17.25% respectively [1] - These two funds, established on December 24, 2024, have cumulative returns of 42.99% and 42.67% as of April 30, 2025 [1] Group 2 - Nine funds under Huatai Fuhua Fund Management Co., Ltd. achieved monthly returns exceeding 10%, including Huatai Fuhua North Exchange Innovation Selected Mixed Fund A and C [2] - The Huatai Fuhua Medical Service Flexible Allocation Mixed Fund A had a return of 12.18% in April and a cumulative return of 55.60% since its inception [3] - The fund manager believes the pharmaceutical industry will show strong anti-cyclical and technological attributes over the next 2 to 3 years, focusing on innovative drugs and high-barrier medical equipment [3] Group 3 - The top-performing funds in April included Huatai Fuhua Medical Service Flexible Allocation Mixed Fund A, with a scale of 4.408 billion yuan, and a cumulative net value of 1.5560 yuan [3] - The two funds, Fuguo Precision Medical Flexible Allocation Mixed Fund A and Zhongyin Innovation Medical Mixed Fund A, also performed well with returns of 11.21% and 10.57% respectively [4][5] - Fuguo Precision Medical Flexible Allocation Mixed Fund A has a cumulative return of 184.98% since its inception [4] Group 4 - A total of 59 mixed funds saw declines exceeding 10% in April, with Tianzhi Quantitative Core Selected Mixed Fund C and A at the bottom with returns of -18.19% and -18.18% respectively [5] - These funds have cumulative returns of -45.73% and -46.21% since their inception [5] - The top ten holdings of these underperforming funds included companies in the optical and semiconductor sectors [5][6]

Core Viewpoint - The report highlights the performance and holdings of the Fuqua Precision Medical Mixed A Fund, indicating its recent decline in net value but strong returns over various time frames [1]. Fund Performance - The latest net value of Fuqua Precision Medical Mixed A is 2.8205 yuan, reflecting a decrease of 1.04% - The fund's return over the past month is 3.36%, ranking 131 out of 1587 in its category - Over the last three months, the fund has achieved a return of 28.71%, ranking 6 out of 1582 - Year-to-date, the fund has returned 26.58%, ranking 17 out of 1574 [1]. Fund Holdings - The top ten stock holdings of Fuqua Precision Medical Mixed A account for a total of 69.71%, with the following allocations: - Baile Tianheng: 9.66% - Haizike: 9.65% - Kelun Pharmaceutical: 9.10% - Huitai Medical: 9.05% - Zai Jian Pharmaceutical-U: 7.84% - Heng Rui Pharmaceutical: 5.95% - Nuo Cheng Jian Hua-U: 5.29% - Xin Nuo Wei: 5.11% - Bai Ji Shen Zhou-U: 4.91% - Zuo Li Pharmaceutical: 3.15% [1]. Fund Manager Background - Zhao Wei, the fund manager, has a master's degree and has held various positions in pharmaceutical research and investment management, including roles at GlaxoSmithKline and several fund management companies - He has been with Fuqua Fund Management since March 2021 and has managed multiple funds prior to his current role [2].